Nonalcoholic fatty liver disease and diabetes: Part II: Treatment

Kyung Soo Kim, Byung Wan Lee, Yong Jin Kim, Dae Ho Lee, Bong Soo Cha, Cheol Young Park

Research output: Contribution to journalReview articlepeer-review

29 Citations (Scopus)


Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders that are often comorbid conditions. Among many proposed treatments, weight reduction is the only approved option for NAFLD to date. However, it is not easy to maintain weight loss by lifestyle modification alone; pharmacological treatments are helpful in this regard. Although many drugs have been investigated, pioglitazone could be a first-line therapy in patients with NAFLD and diabetes. Many more drugs are currently being developed and investigated, and it is likely that combination strategies will be used for future treatment of NAFLD and diabetes. Attention should be paid to the management of NAFLD and diabetes and efforts should be made to intervene early and individualize treatment of NAFLD in patients with diabetes.

Original languageEnglish
Pages (from-to)127-143
Number of pages17
JournalDiabetes and Metabolism Journal
Issue number2
Publication statusPublished - 2019 Apr 1

Bibliographical note

Publisher Copyright:
Copyright © 2019 Korean Diabetes Association.

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Nonalcoholic fatty liver disease and diabetes: Part II: Treatment'. Together they form a unique fingerprint.

Cite this